Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction

Details

Serval ID
serval:BIB_3BF6733E4762
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction
Journal
Circulation
Author(s)
Pacher  P., Liaudet  L., Bai  P., Mabley  J. G., Kaminski  P. M., Virag  L., Deb  A., Szabo  E., Ungvari  Z., Wolin  M. S., Groves  J. T., Szabo  C.
ISSN
1524-4539 (Electronic)
Publication state
Published
Issued date
02/2003
Volume
107
Number
6
Pages
896-904
Notes
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Feb 18
Abstract
BACKGROUND: Increased oxidative stress and dysregulation of nitric oxide have been implicated in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Peroxynitrite is a reactive oxidant produced from nitric oxide and superoxide in various forms of cardiac injury. Using a novel metalloporphyrinic peroxynitrite decomposition catalyst, FP15, and nitric oxide synthase inhibitors or knockout mice, we now delineate the pathogenetic role of peroxynitrite in rodent models of DOX-induced cardiac dysfunction. METHODS AND RESULTS: Mice received a single injection of DOX (25 mg/kg IP). Five days after DOX administration, left ventricular performance was significantly depressed, and high mortality was noted. Treatment with FP15 and an inducible nitric oxide synthase inhibitor, aminoguanidine, reduced DOX-induced mortality and improved cardiac function. Genetic deletion of the inducible nitric oxide synthase gene was also accompanied by better preservation of cardiac performance. In contrast, inhibition of the endothelial isoform of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality. FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities. Furthermore, FP15 prevented the DOX-induced increase in lipid peroxidation, nitrotyrosine formation, and metalloproteinase activation in the heart but not NAD(P)H-driven superoxide generation. Peroxynitrite neutralization did not interfere with the antitumor effect of DOX. FP15 also decreased ischemic injury in rats and improved cardiac function and survival of mice in a chronic model of DOX-induced cardiotoxicity. CONCLUSIONS: Thus, peroxynitrite plays a key role in the pathogenesis of DOX-induced cardiac failure. Targeting peroxynitrite formation may represent a new cardioprotective strategy after DOX exposure or in other conditions associated with peroxynitrite formation, including myocardial ischemia/reperfusion injury.
Keywords
Acute Disease Animals Catalysis/drug effects Chronic Disease Creatine Kinase/blood Disease Models, Animal Doxorubicin/*toxicity Enzyme Inhibitors/pharmacology Heart/*drug effects/physiopathology Heart Failure, Congestive/*chemically induced/physiopathology/prevention & control L-Lactate Dehydrogenase/blood Male Metalloporphyrins/*pharmacology Mice Mice, Inbred BALB C Mice, Inbred C57BL Mice, Knockout Nitric Oxide Synthase/antagonists & inhibitors/genetics/metabolism Nitric Oxide Synthase Type II Nitric Oxide Synthase Type III Oxidative Stress/drug effects/genetics Peroxynitrous Acid/*metabolism Survival Rate
Pubmed
Web of science
Open Access
Yes
Create date
24/01/2008 17:00
Last modification date
20/08/2019 13:32
Usage data